5980 Horton Street
Ligand Pharmaceuticals’ OmniAb provides the industry’s only offering with multiple transgenic animal species, strategically built to optimally harness the unparalleled power of Biological Intelligence. Beginning with OmniRat® in 2012, this suite of animal technologies has expanded over the years with the addition of OmniFlic® and OmniMouse® in 2014, OmniChicken® in 2016, OmniClic® in 2019, and OmniTaur™ in 2020. In 2020, OmniAb’s offerings also broadened to include antigen design and other technologies that supplement the animal offerings. As a leader in transgenic animal technology, we are committed to providing technologies that enable and enhance the discovery of therapeutic antibodies
5 articles with OmniAb
OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates.
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences.
Ligand Pharmaceuticals Incorporated announced the completion of its expected tax-free distribution of 100% of Ligand’s interest in its subsidiary OmniAb on a pro rata basis to Ligand shareholders of record as of October 26, 2022.
OmniAb, Inc. announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated and the subsequent business combination with Avista Public Acquisition Corp. II, resulting in OmniAb becoming an independent publicly traded company.
IPA today announced that its subsidiary, Talem Therapeutics LLC (“Talem”), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated.